NeuroOne Medical Technologies Co. (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) was the target of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 308,500 shares, a decline of 15.5% from the March 31st total of 365,300 shares. Based on an average trading volume of 194,700 shares, the short-interest ratio is presently 1.6 days. Approximately 1.4% of the shares of the company are short sold.

Institutional Investors Weigh In On NeuroOne Medical Technologies

An institutional investor recently bought a new position in NeuroOne Medical Technologies stock. Perkins Capital Management Inc. purchased a new stake in shares of NeuroOne Medical Technologies Co. (NASDAQ:NMTC) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 150,000 shares of the company’s stock, valued at approximately $134,000. Perkins Capital Management Inc. owned 0.63% of NeuroOne Medical Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Performance

Shares of NeuroOne Medical Technologies stock opened at $1.13 on Friday. NeuroOne Medical Technologies has a 52-week low of $0.85 and a 52-week high of $2.00. The stock’s 50-day simple moving average is $1.17 and its 200 day simple moving average is $1.25. The stock has a market capitalization of $29.30 million, a P/E ratio of -1.66 and a beta of 0.81.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.14) earnings per share (EPS) for the quarter. NeuroOne Medical Technologies had a negative net margin of 478.41% and a negative return on equity of 267.82%. The firm had revenue of $0.98 million during the quarter.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders.